ACADIA Pharmaceuticals (ACAD) Set to Announce Quarterly Earnings on Monday

Posted by MarketBeat News on Aug 6th, 2022

ACADIA Pharmaceuticals (NASDAQ:ACAD – Get Rating) is scheduled to be issuing its quarterly earnings data after the market closes on Monday, August 8th. Analysts expect the company to announce earnings of ($0.25) per share for the quarter. Parties interested in listening to the company’s conference call can do so using this link.

ACADIA Pharmaceuticals (NASDAQ:ACAD – Get Rating) last released its quarterly earnings data on Wednesday, May 4th. The biopharmaceutical company reported ($0.70) EPS for the quarter, missing the consensus estimate of ($0.49) by ($0.21). ACADIA Pharmaceuticals had a negative net margin of 43.50% and a negative return on equity of 40.52%. The business had revenue of $115.47 million for the quarter, compared to the consensus estimate of $122.22 million. During the same quarter last year, the business earned ($0.42) EPS. ACADIA Pharmaceuticals’s revenue for the quarter was up 8.4% compared to the same quarter last year. On average, analysts expect ACADIA Pharmaceuticals to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

ACADIA Pharmaceuticals Stock Up 5.2 %

ACAD stock opened at $16.44 on Friday. ACADIA Pharmaceuticals has a 52 week low of $12.24 and a 52 week high of $28.06. The company has a fifty day simple moving average of $15.75 and a two-hundred day simple moving average of $20.22. The firm has a market capitalization of $2.66 billion, a P/E ratio of -12.36 and a beta of 0.71.

Wall Street Analysts Forecast Growth

ACAD has been the subject of several research reports. SVB Leerink lowered their price objective on shares of ACADIA Pharmaceuticals from $31.00 to $27.00 and set an “outperform” rating for the company in a research report on Monday, July 11th. Citigroup lowered shares of ACADIA Pharmaceuticals from a “buy” rating to a “neutral” rating and lowered their target price for the stock from $19.00 to $15.00 in a report on Friday. Royal Bank of Canada lowered their target price on shares of ACADIA Pharmaceuticals from $32.00 to $26.00 and set an “outperform” rating for the company in a report on Tuesday, June 21st. Oppenheimer lowered their target price on shares of ACADIA Pharmaceuticals from $23.00 to $19.00 and set a “market perform” rating for the company in a report on Tuesday, June 21st. Finally, JPMorgan Chase & Co. lowered shares of ACADIA Pharmaceuticals from an “overweight” rating to a “neutral” rating in a report on Tuesday, June 21st. One research analyst has rated the stock with a sell rating, ten have issued a hold rating and seven have given a buy rating to the company. According to MarketBeat, the stock has an average rating of “Hold” and an average price target of $24.50.

Institutional Investors Weigh In On ACADIA Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Point72 Hong Kong Ltd lifted its holdings in ACADIA Pharmaceuticals by 664.7% during the 1st quarter. Point72 Hong Kong Ltd now owns 6,003 shares of the biopharmaceutical company’s stock valued at $145,000 after buying an additional 5,218 shares in the last quarter. Bridgewater Associates LP purchased a new position in ACADIA Pharmaceuticals during the 1st quarter valued at about $218,000. Bridgefront Capital LLC purchased a new position in ACADIA Pharmaceuticals during the 1st quarter valued at about $224,000. Guggenheim Capital LLC increased its position in ACADIA Pharmaceuticals by 16.6% during the 1st quarter. Guggenheim Capital LLC now owns 10,753 shares of the biopharmaceutical company’s stock valued at $261,000 after purchasing an additional 1,533 shares during the period. Finally, Mariner LLC purchased a new position in ACADIA Pharmaceuticals during the 1st quarter valued at about $277,000. Institutional investors own 91.74% of the company’s stock.

ACADIA Pharmaceuticals Company Profile

(Get Rating)

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis.